William Klitgaard - Laboratory President- Enlighten Health
LH Stock | USD 199.10 0.87 0.44% |
President
Mr. William T. Klitgaard is President Enlighten Health of the company since March 2015. Prior to that Mr. Klitgaard was Chief Information Officer for Covance Inc. since April 2012 where he had overall responsibility for the Covance Global IT organization. Prior to that Mr. Klitgaard served 12 years as Covances Chief Financial Officer. Mr. Klitgaard joined Covance as Corporationrationrate Treasurer in 1996 was appointed to manage the Companys strategic planning and corporate development activities in 1999 and was appointed Chief Financial Officer in 2000 since 2015.
Age | 61 |
Tenure | 9 years |
Address | 358 South Main Street, Burlington, NC, United States, 27215 |
Phone | 336 229 1127 |
Web | https://www.labcorp.com |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.08. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
Showing other executives | PRESIDENT Age | ||
Tristan Orpin | Illumina | 49 | |
Virginia Drosos | Myriad Genetics | 53 | |
Henrik AncherJensen | Agilent Technologies | 59 | |
Patrick Durbin | Thermo Fisher Scientific | 51 | |
Ralph McDade | Myriad Genetics | 62 | |
Jacquie Ross | Illumina | N/A | |
Kenneth Apicerno | Thermo Fisher Scientific | N/A | |
Seth Hoogasian | Thermo Fisher Scientific | 61 | |
Karen McGinnis | Illumina | 50 | |
Stephen Williamson | Thermo Fisher Scientific | 57 | |
Charles Dadswell | Illumina | 65 | |
Joakim Weidemanis | Danaher | 55 | |
Mark Doak | Agilent Technologies | 63 | |
Lloyd Sanders | Myriad Genetics | 57 | |
Patrick Weiss | Twist Bioscience Corp | 48 | |
Gregory Herrema | Thermo Fisher Scientific | 52 | |
Peter Hornstra | Thermo Fisher Scientific | 59 | |
Daniel Comas | Danaher | 55 | |
Paul Bianchi | Illumina | 53 | |
Patrick Finn | Twist Bioscience Corp | 52 | |
Dominique Grau | Agilent Technologies | 65 |
Management Performance
Return On Equity | 0.0423 | ||||
Return On Asset | 0.0377 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Klitgaard, President- Enlighten Health | ||
Paul Surdez, IR Contact Officer | ||
Deborah Tanner, CEO - Covance Drug Development (Covance) | ||
Stephen Anderson, Vice President Investor Relations | ||
Sanders Williams, Independent Director | ||
JD MD, President EVP | ||
Amy Summy, Executive Vice President Chief Marketing Officer | ||
Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
Robert Pringle, Senior Treasurer | ||
Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
Lisa Uthgenannt, Chief Human Resource Officer, Senior Vice President | ||
Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
D Gilliland, Independent Director | ||
Gary Huff, CEO, LabCorp Diagnostics | ||
JeanLuc Belingard, Independent Director | ||
Clarissa Willett, IR Contact Officer | ||
Peter Neupert, Lead Independent Director | ||
Robert Williams, Independent Director | ||
Megan MPH, Executive Officer | ||
Chas Cook, VP Relations | ||
Garheng Kong, Independent Director | ||
Gary Gilliland, Independent Director | ||
David King, Chairman of the Board, President, Chief Executive Officer | ||
Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
Mark Brecher, Senior Vice President Chief Medical Officer | ||
Samuel Eberts, Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer | ||
Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
Edward Dodson, Chief Accounting Officer and Sr. VP | ||
Robert Mittelstaedt, Lead Independent Director | ||
Anita Graham, Executive Officer | ||
Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
Michelle Abelson, Laboratory Operations | ||
Jonathan DiVincenzo, Executive International | ||
John Ratliff, Chief Executive Officer - Covance Drug Development | ||
Kerrii Anderson, Independent Director | ||
Paul MD, Ex Devel | ||
Marcia Eisenberg, Chief VP | ||
John Treadwell, Vice Initiatives | ||
Kathryn Wengel, Independent Director | ||
Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
James Boyle, Executive VP and CEO of Labcorp Diagnostics | ||
Richelle Parham, Independent Director | ||
Jeffrey Davis, Independent Director | ||
Christin ODonnell, Vice Relations | ||
Deborah SesokPizzini, SVP Officer | ||
Scott Frommer, Vice President - Investor Relations | ||
MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0423 | ||||
Return On Asset | 0.0377 | ||||
Profit Margin | 0.03 % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 22.42 B | ||||
Shares Outstanding | 84.13 M | ||||
Shares Owned By Insiders | 0.33 % | ||||
Shares Owned By Institutions | 98.26 % | ||||
Number Of Shares Shorted | 1.92 M | ||||
Price To Earning | 12.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.46) | Dividend Share 2.88 | Earnings Share 4.32 | Revenue Per Share 139.628 | Quarterly Revenue Growth 0.035 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.